Phase 1 Sjogren's Syndrome Trial, Recruiting NCT07123519 Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. Condition: Sjogren's Syndrome
Back to Sjogrens Syndrome

Phase 1 Sjogren's Syndrome Trial, Recruiting

NCT07123519
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old (inclusive).

  • Your blood counts meet minimum levels — specifically, your infection-fighting white blood cells and red blood cells are above certain thresholds (confirm with trial site for exact values).

  • Your liver is functioning well enough, based on blood test results within an acceptable range.

  • Your kidneys are working at a sufficient level, based on a standard kidney function calculation.

  • Your blood clotting ability is within an acceptable range.

  • Your heart and circulation are stable.

  • If you are able to have children, you agree to use an approved form of contraception (or abstain) during the trial and for at least 12 months after treatment ends.

  • If you are a woman who could become pregnant, you have a negative pregnancy blood test within 7 days before joining, and you are not currently breastfeeding.

  • You are willing to take part voluntarily and sign a consent form.

  • You have been diagnosed with one of the following conditions that has not responded to standard treatments or has come back after treatment:

    • Lupus (SLE) — specifically with kidney involvement (lupus nephritis) or very low platelet counts (immune thrombocytopenia), confirmed by specific medical tests and after trying at least two standard treatments without enough improvement.
    • Sjögren's syndrome — confirmed by recognised diagnostic criteria, with a high disease activity score, a positive blood marker (anti-SSA/Ro), and disease that has continued or returned despite at least 6 months of standard treatment.
    • Systemic sclerosis (scleroderma) — confirmed by recognised criteria, with positive related antibodies, and either widespread skin hardening or active lung involvement, persisting or worsening despite standard treatment.
    • Inflammatory muscle disease (myositis) — such as dermatomyositis or polymyositis, confirmed by recognised criteria, with positive related antibodies and measurable muscle or lung involvement, persisting or worsening despite standard treatment.
    • ANCA-associated vasculitis — a type of blood vessel inflammation confirmed by recognised criteria, with positive related antibodies and a high disease activity score, persisting or returning despite standard treatment.
    • Antiphospholipid syndrome — confirmed by recognised criteria, with positive related antibodies on at least two separate tests, and clotting events that have returned despite standard blood-thinning treatment; or a severe ("catastrophic") form involving three or more organs.

Who may not be able to join:

  • You have a history of serious allergic reactions to medicines, or you are known to have a highly allergic constitution.
  • You have an active infection (bacterial, viral, fungal, or other) that is not currently controlled.
  • You have a brain or nervous system condition that is not caused by your underlying disease (confirm with trial site).
  • Your heart is not strong enough to safely tolerate the treatments used in this study.
  • You were born with an immune system condition that causes you to lack certain antibodies (immunoglobulin deficiency).
  • You have had a cancer diagnosis within the past 5 years.
  • Your kidneys have reached end-stage failure.
  • You have active hepatitis B, hepatitis C, HIV, or syphilis, based on specific blood test results.
  • You have had a blood clot in a deep vein or in your lungs within the past 6 months before screening.
  • You have a psychiatric disorder or severe memory/thinking difficulties.
  • You have taken part in another clinical trial within the past 3 months.
  • You have recently received certain immunosuppressive or biological medicines within a specific timeframe before joining (confirm exact timeframes with trial site).
  • You are currently pregnant or planning to become pregnant.
  • The trial doctor has identified another reason that means it would not be appropriate for you to join.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 15900225626

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
13 August 2025
Est. completion
13 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Treatment-Emergent Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov